MetaCap

Kyverna Therapeutics Inc. (KYTX)

NASDAQ: KYTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

4.26-0.11 (-2.52%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KYTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$269.33M
EPS (TTM)
-$2.75
52-week range
4.18 – 13.67
Day range
4.18 – 4.58
Volume / Avg
1.34M / 867.28K
Beta
—

52-week range

$4.18$13.67

KYTX stock today

Shares of Kyverna Therapeutics (KYTX) finished lower on Nov 20 at $4.26, a drop of 2.52% or $0.11 per share, versus the S&P 500's 3.70% decline. At this level, KYTX sits near the bottom of its 52-week range of $4.18 to $13.67: 68.8% below the high, set on Dec 15, 2025 and 2.0% above the low. KYTX is down 54.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 39.9%.

Kyverna Therapeutics has posted a net loss over the last twelve months (EPS of -$2.75), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Kyverna Therapeutics

Company profile

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Warner Biddle
Headquarters
Emeryville, CA
Employees
172
IPO year
2024

Financial highlights

Full financials

Kyverna Therapeutics reported a net loss of $161.3 million, compared with a loss of $127.5 million a year earlier. Diluted earnings per share came in at -$3.64.

Kyverna Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-161.31M$-127.48M$-60.37M
EPS (diluted)$-3.64$-3.33$-89.61

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$30.40+613.62%

  • Strong buy 2
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $25.00High $33.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.68 vs $-0.68

KYTX news

All KYTX news

Kyverna Therapeutics peers

Health Care sector
KYTX peer companies
CompanyPrice% ChgMarket capCompare
AGENAgenus Inc.5.97-2.77%$270.12Mvs KYTX
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs KYTX
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs KYTX
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs KYTX
DTILPrecision BioSciences Inc.7.40+7.09%$282.46Mvs KYTX
SABSSAB Biotherapeutics Inc.2.81-3.44%$253.15Mvs KYTX
EDITEditas Medicine Inc.1.64-4.09%$253.12Mvs KYTX
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs KYTX

Indexes, lists and sector

Kyverna Therapeutics stock FAQ

What is Kyverna Therapeutics's stock price today?

KYTX last traded at $4.26 as of Nov 20, 4:00 PM EST, down 2.52% on the day. Prices are delayed at least 15 minutes.

Who is Kyverna Therapeutics's CEO?

Mr. Warner Biddle is the chief executive officer of Kyverna Therapeutics Inc., which has about 172 employees.

What is the KYTX 52-week high?

The 52-week high for KYTX is $13.67 and the 52-week low is $4.18. The stock is currently 68.8% below its high.

Compare KYTX